CL2015002677A1 - Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial. - Google Patents

Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.

Info

Publication number
CL2015002677A1
CL2015002677A1 CL2015002677A CL2015002677A CL2015002677A1 CL 2015002677 A1 CL2015002677 A1 CL 2015002677A1 CL 2015002677 A CL2015002677 A CL 2015002677A CL 2015002677 A CL2015002677 A CL 2015002677A CL 2015002677 A1 CL2015002677 A1 CL 2015002677A1
Authority
CL
Chile
Prior art keywords
selenium
compositions
diseases
prevention
treatment
Prior art date
Application number
CL2015002677A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Kwiatkowski
Power Ronan
Egan Casey
Lan Zi-Jian
Xiao Rijin
Jackson Lewis
Yiannikouris Alexandros
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of CL2015002677A1 publication Critical patent/CL2015002677A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2015002677A 2013-03-15 2015-09-14 Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial. CL2015002677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002677A1 true CL2015002677A1 (es) 2016-12-09

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002677A CL2015002677A1 (es) 2013-03-15 2015-09-14 Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.

Country Status (15)

Country Link
US (1) US9833486B2 (enExample)
EP (1) EP2968404A4 (enExample)
JP (1) JP6313418B2 (enExample)
KR (1) KR102245702B1 (enExample)
CN (3) CN114533753A (enExample)
AU (1) AU2014228785B2 (enExample)
BR (1) BR112015022514A2 (enExample)
CA (1) CA2903845C (enExample)
CL (1) CL2015002677A1 (enExample)
HK (1) HK1216506A1 (enExample)
MX (1) MX359626B (enExample)
RU (1) RU2663127C2 (enExample)
SG (2) SG11201507061XA (enExample)
WO (1) WO2014144776A1 (enExample)
ZA (1) ZA201506759B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022936A2 (pt) 2013-03-14 2017-07-18 J Schentag Jerome vesículas de colestossoma para a incorporação de moléculas em quilomícrons
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
AU2019261476B2 (en) * 2018-04-25 2021-11-18 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
KR20230029674A (ko) * 2020-06-29 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 생물반응기로부터의 샘플을 분석하기 위한 자동화 시스템 및 방법
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
EP1643865A1 (en) * 2003-06-04 2006-04-12 Willem Jacob Serfontein Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US20100247679A1 (en) 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
CN102056499B (zh) * 2007-10-16 2014-12-31 阿克特基因组学有限公司 用于调节脂质代谢的组合物
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
RU2012120785A (ru) * 2009-10-22 2013-11-27 ПРОПАНК ПиТиУай ЛТД Фармацевтические композиции
JP5896421B2 (ja) * 2010-04-22 2016-03-30 国立大学法人京都大学 多能性幹細胞から骨格筋または骨格筋前駆細胞への分化誘導法
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Also Published As

Publication number Publication date
CA2903845A1 (en) 2014-09-18
JP6313418B2 (ja) 2018-04-18
SG11201507061XA (en) 2015-10-29
JP2016516058A (ja) 2016-06-02
AU2014228785B2 (en) 2018-01-25
KR20150132374A (ko) 2015-11-25
NZ711842A (en) 2021-04-30
US20160113977A1 (en) 2016-04-28
RU2015139742A (ru) 2017-04-21
AU2014228785A1 (en) 2015-09-24
US9833486B2 (en) 2017-12-05
CN114984038A (zh) 2022-09-02
MX2015013275A (es) 2015-12-11
CA2903845C (en) 2022-08-23
CN105377271A (zh) 2016-03-02
EP2968404A1 (en) 2016-01-20
HK1216506A1 (zh) 2016-11-18
KR102245702B1 (ko) 2021-04-28
MX359626B (es) 2018-10-01
ZA201506759B (en) 2017-03-29
CN114533753A (zh) 2022-05-27
EP2968404A4 (en) 2017-01-04
BR112015022514A2 (pt) 2017-07-18
SG10202101918RA (en) 2021-03-30
WO2014144776A1 (en) 2014-09-18
RU2663127C2 (ru) 2018-08-01

Similar Documents

Publication Publication Date Title
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX2017001512A (es) Compuestos activos hacia bromodominios.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016002971A1 (es) Combinación.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CR20160433A (es) Nuevos compuestos
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
MX384185B (es) Composicion en forma de emulsion de aceite en agua que comprende semillas molidas en mostaza blanca o amarilla.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
CL2016000397A1 (es) Tratamiento contra el cáncer